07:16 AM EDT, 03/16/2026 (MT Newswires) -- Esperion Therapeutics ( ESPR ) said Monday its cholesterol lowering therapy bempedoic acid received multiple Class 1 recommendations in the 2026 American College of Cardiology/American Heart Association multisociety guideline for the management of dyslipidemia.

The company said the guideline provides the strongest endorsement for bempedoic acid in patients with statin intolerance, and in primary and secondary prevention patients with severe hypercholesterolemia.

Shares of the company were up 4.1% in Monday premarket trading.